MDR-selective compound that exhibits a robust Pgp-dependent toxic activity across diverse cancer cell lines
NSC57969 is a MDR-selective compound that exhibits a robust Pgp-dependent toxic activity across diverse cancer cell lines. NSC57969 shows profound toxicity against doxorubicin resistant Brca1-/-;p53-/- spontaneous mouse mammary carcinoma cells. NSC57969 eradicates P-glycoprotein expression in doxorubicin resistant brca1-/-;p53-/- spontaneous mouse mammary carcinoma, and MES-SA/Dx5 cells. However treatment of normal cells (hCMEC/D3 cells) with NSC57969 does not induce loss of Pgp.
Molecular cancer therapeutics, 16(1), 45-56 (2016-10-21)
Despite significant progress, resistance to chemotherapy is still the main reason why cancer remains a deadly disease. An attractive strategy is to target the collateral sensitivity of otherwise multidrug resistant (MDR) cancer. In this study, our aim was to catalog
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.